<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057642</url>
  </required_header>
  <id_info>
    <org_study_id>#4358</org_study_id>
    <secondary_id>R21MH066388</secondary_id>
    <secondary_id>DSIR SE-SC</secondary_id>
    <nct_id>NCT00057642</nct_id>
  </id_info>
  <brief_title>Improving Retention of Hispanics Receiving Antidepressant Therapy</brief_title>
  <official_title>Improving Hispanic Retention in Antidepressant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will develop an intervention that will increase the retention of Hispanics with&#xD;
      major depression in antidepressant therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite major advances in the treatment of psychiatric disorders, Hispanics continue to&#xD;
      underutilize mental health services relative to their own mental health needs. Cultural&#xD;
      factors are important causes of underutilization. To date, however, attempts to boost&#xD;
      utilization by improving the cultural congruence of psychiatric services have not focused on&#xD;
      retaining Hispanics in antidepressant therapy.&#xD;
&#xD;
      Motivational Interviewing (MI) is a time-limited psychotherapy that has successfully improved&#xD;
      treatment retention among patients with dually diagnosed substance abuse and psychiatric&#xD;
      disorders. During Phase I of this study, MI is adapted for use as an adjunctive therapy with&#xD;
      antidepressant treatment and culturally adapted to Hispanic participants. In Phase II,&#xD;
      participants receive sertraline for 12 weeks and participate in four sessions of MI therapy&#xD;
      as a supplementary intervention designed to encourage treatment retention. Participants who&#xD;
      are intolerant to sertraline or have an inadequate response by Week 6 are switched to&#xD;
      venlafaxine ER while continuing to receive MI and to complete study assessments. A follow-up&#xD;
      interview is conducted 6 months after the termination of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention percentage</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proportion of weeks in treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms on the Hamilton Depression scale</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in treatment</measure>
    <time_frame>84 days</time_frame>
    <description>Sum of days in treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional impairment on the Sheehan Disability Scale</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived quality of life</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Depression</condition>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Sertraline, venlafaxine, bupropion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is an open trial so there is only one arm using standard antidepressant medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <arm_group_label>Sertraline, venlafaxine, bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine Extended Release</intervention_name>
    <arm_group_label>Sertraline, venlafaxine, bupropion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnostic Statistical Manual, 4th edition criteria for Major Depressive Disorder&#xD;
&#xD;
          -  Patients who self-identify as Hispanic and are Spanish-dominant, English-dominant, or&#xD;
             bilingual&#xD;
&#xD;
          -  Acceptable methods of contraception&#xD;
&#xD;
          -  Hamilton Depression Rating Scale score &gt;= 18 at Visit 1&#xD;
&#xD;
          -  Sertraline or venlafaxine ER is clinically appropriate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of schizophrenia, bipolar affective disorder, schizoaffective disorder,&#xD;
             depression with psychotic symptoms, or organic brain syndrome&#xD;
&#xD;
          -  DSM-IV criteria for alcohol or substance abuse or dependence during the 6 months prior&#xD;
             to screening&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  At risk for committing suicide&#xD;
&#xD;
          -  Clinically significant renal, pulmonary, cerebrovascular, cardiovascular,&#xD;
             gastrointestinal, or endocrine disorders&#xD;
&#xD;
          -  Glaucoma, history of increased intraocular pressure (IOP), or at risk for having&#xD;
             increased IOP&#xD;
&#xD;
          -  Untreated or unstable hypertension&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities or abnormal electrocardiogram&#xD;
&#xD;
          -  Medical conditions that might interfere with the process of drug absorption,&#xD;
             metabolism, or elimination&#xD;
&#xD;
          -  Clinically significant thyroid dysfunction (except patients who are stable and&#xD;
             asymptomatic on thyroid replacement therapy)&#xD;
&#xD;
          -  Current or past history of seizure disorder (except febrile seizure in childhood)&#xD;
&#xD;
          -  History of failed sertraline or venlafaxine treatment for at least 4 weeks at adequate&#xD;
             doses&#xD;
&#xD;
          -  Allergy or hypersensitivity to sertraline or venlafaxine&#xD;
&#xD;
          -  History of two failed selective serotonin reuptake inhibitor (SSRI) trials for major&#xD;
             depression at adequate doses and duration&#xD;
&#xD;
          -  Monoamine oxidase inhibitors (MAOIs) or fluoxetine within 4 weeks prior to screening,&#xD;
             or other SSRIs, antidepressants, neuroleptics, mood stabilizers, buspirone,&#xD;
             benzodiazepines, or other psychotropic drugs (except zolpidem for insomnia) within 2&#xD;
             weeks prior to screening&#xD;
&#xD;
          -  Electroconvulsive Therapy (ECT) within the last 3 months&#xD;
&#xD;
          -  Effective medication or psychotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Lewis-Fernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University, NY State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>April 4, 2003</study_first_submitted>
  <study_first_submitted_qc>April 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2003</study_first_posted>
  <last_update_submitted>August 16, 2013</last_update_submitted>
  <last_update_submitted_qc>August 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hispanic Americans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

